iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) will announce its second-quarter financial results on August 10, 2022, after market closure. The results will be followed by a conference call at 4:30 PM ET. This announcement highlights iCAD's ongoing commitment to transparency and investor engagement as it continues to provide innovative solutions in cancer detection and therapy.
Details
News Market Reaction – ICAD
The recorded move for ICAD in the trading session of this news was +1.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022.
August 10, 2022 at 4:30 PM ET
Domestic: 888-506-0062
International: 973-528-0011
Conference ID: 718241
Webcast: https://www.webcaster4.com/Webcast/Page/2879/46166
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Investor Inquiries:
iCAD Investor Relations
ir@icadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.